Manufacturing

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California.

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

Moderna’s new facility is expected to produce 500 million vaccine doses per year.

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

New excipients for protein-based drug products reduce viscosity while maintaining protein stability.

Thermo Fisher’s new Swiss facility will initially produce CSL Limited’s recombinant factor IX product Idelvion.

The complexity of newer biotherapeutic molecules calls for alternative drug delivery strategies.

The intranasal route of administration is showing clinical promise, particularly for COVID-19, but there are multiple hurdles to overcome to ensure successful formulation.

Large-scale single-use bioreactors prove successful as limits are tested.

SUB bioreactor performance has had seen its limits and successes.

Early control architecture decisions can impact a facility’s long-term growth, flexibility, and efficiency.

Establishing a data management strategy in-lab is a first step in generating successful analytical studies.

The new LabVantage Enterprise SaaS adds full configurability and custom interfacing capabilities.

NewAge Industries has completed a plant expansion that added new cleanrooms to its headquarters in Southampton, Pa.

According to Charles River Laboratories, when asked how long it takes for a drug to be developed and approved for market in the United States, only 10% of 1,500 Americans polled correctly estimated that it takes between 10 and 15 years.

Researchers in China report test results for a microneedle patch for COVID-19 vaccine delivery.

In an amendment to their existing contract manufacturing agreement, Celsian and Poly Pharm expand GEN-1 program collaboration to add clinical and commercial batches of investigational vaccine.

New data finds J&J COVID-19 vaccine and booster to provide increased protection against COVID-19.

Lonza’s investment in its Stein and Basel facilities in Switzerland aims to expand its overall drug product development and manufacturing services.

Celularity and Oncternal’s collaboration will focus on therapeutics targeting Orphan Receptor 1, which is linked to aggression and survival in solid tumor cells.

CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.

Repligen and Navigo’s novel ligand could be the first to address antibody aggregation in low pH elution buffers.

AGC Biologics is expanding manufacturing capacity at its Heidelberg, Germany, facility for plasmid DNA and messenger RNA.

Moderna’s new single-dose vaccine will be a booster for both COVID-19 and the flu.

AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the advance purchase agreement for the delivery of Vaxzevria.